NEW YORK (GenomeWeb News) – Battelle said on Tuesday that it has made an investment of an undisclosed amount in CosmosID for the development of a metagenomics software-based solution for microbial identification.
The investment from Battelle is part of $4 million in financing that CosmosID recently received to support its efforts "to deliver pathogen identification in a single, rapid, and accurate service," Battelle said, adding that it is partnering with the College Park, Md.-based company to develop and market microbial metagenomics toolkits for public safety and medical treatment applications.
CosmosID's technology called MetaSeq Genomics uses unassembled reads from next-generation sequencing, probabilistic algorithms, and reference databases to identify pathogens, and antibiotic resistance and virulence factors. The software, which is scalable and updated iteratively, is targeted for diagnostic test development in the markets of public safety and security, medical treatment, environmental monitoring, and drug development, Battelle said.
Privately held CosmosID was founded in 2007 by Rita Colwell, former director of the US National Science Foundation and currently distinguished professor at Johns Hopkins University Bloomberg School of Public Health and the University of Maryland.